Physician profile
Yi Chen
NPI 1013621184
$10,575.58
in general payments reported to CMS, 2019-2025
56 companies · $4,377 in 2025
The $4,377 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,644 · 2024: $3,555 · 2025: $4,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,838 · Education: $1,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,837.91 |
| Education | $1,737.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,268.05 | 2023-2025 | Vyloy, Xospata, Padcev |
| Astrazeneca Pharmaceuticals Lp | $945.84 | 2023-2025 | Imfinzi, Enhertu, Tagrisso |
| Merck Sharp & Dohme LLC | $810.07 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Biotech, INC. | $644.33 | 2024-2025 | Carvykti, Darzalex, Tecvayli |
| Pfizer INC. | $621.78 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $541.52 | 2023-2025 | |
| Incyte Corporation | $418.81 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| E.R. Squibb & Sons, L.L.C. | $368.27 | 2023-2025 | Opdivo, Reblozyl |
| Celgene Corporation | $366.95 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $348.51 | 2024-2025 | Iclusig, Fruzaqla, Ninlaro |
| Glaxosmithkline, LLC. | $327.47 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Array Biopharma INC | $271.27 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Gilead Sciences, INC. | $203.71 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $194.54 | 2023-2025 | Libtayo |
| Genzyme Corporation | $189.59 | 2023-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $186.06 | 2023 | Prolaris |
| Seagen INC. | $179.07 | 2023 | Tukysa, Padcev |
| Tactile Systems Technology INC | $161.03 | 2023 | Flexitouch Plus, Entre Plus |
| Eisai INC. | $153.57 | 2023-2025 | |
| Lilly USA, LLC | $153.19 | 2023-2025 | Verzenio, Jaypirca |
| Genmab U.S., INC. | $151.89 | 2024-2025 | Epkinly |
| Daiichi Sankyo INC. | $148.82 | 2024-2025 | Enhertu, Datroway |
| Aveo Pharmaceuticals, INC. | $128.50 | 2025 | |
| Geron Corporation | $127.54 | 2024-2025 | Rytelo |
| Stemline Therapeutics INC. | $125.60 | 2024-2025 | Orserdu |
| Abbvie INC. | $122.72 | 2024-2025 | |
| Taiho Oncology, INC. | $98.95 | 2023-2024 | |
| Pharmaessentia USA Corporation | $90.15 | 2025 | Besremi |
| Coherus Oncology, INC. | $87.21 | 2024-2025 | Loqtorzi |
| Deciphera Pharmaceuticals INC. | $73.85 | 2023-2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $67.58 | 2023-2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $67.16 | 2024-2025 | Onivyde, Somatuline Depot |
| Alexion Pharmaceuticals, INC. | $65.63 | 2023-2024 | Ultomiris |
| Sobi, INC | $61.44 | 2024-2025 | |
| Puma Biotechnology, INC. | $53.03 | 2024-2025 | |
| Kyowa Kirin, INC. | $49.57 | 2023-2025 | Poteligeo |
| Iovance Biotherapeutics, INC. | $49.06 | 2025 | Amtagvi |
| Morphosys, US INC. | $48.24 | 2023 | Monjuvi |
| Beone Medicines USA, INC. | $47.54 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $45.31 | 2025 | Pyrukynd |
| Pharmacyclics LLC, An Abbvie Company | $44.86 | 2023 | Imbruvica, Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $43.47 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $43.33 | 2024-2025 | Sylvant |
| Syndax Pharmaceuticals, INC. | $42.69 | 2025 | |
| Apellis Pharmaceuticals, INC. | $40.70 | 2023 | Empaveli |
| Janssen Pharmaceuticals, INC | $40.22 | 2025 | |
| Emd Serono, INC. | $38.90 | 2024 | |
| Rigel Pharmaceuticals, INC. | $31.07 | 2024 | Tavalisse, Rezlidhia |
| Octapharma USA, INC. | $30.00 | 2023 | Octagam Immune Globulin (Human) |
| Cti Biopharma Corp. | $25.86 | 2023 | Vonjo |
| Immunogen, INC. | $25.20 | 2024 | Elahere |
| Legend Biotech USA INC. | $24.21 | 2025 | Carvykti |
| Beigene USA, INC. | $23.90 | 2025 | Brukinsa |
| Servier Pharmaceuticals LLC | $22.22 | 2025 | |
| Karyopharm Therapeutics INC. | $21.46 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.07 | 2024 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.